NMC Health founder faces $5.4bn fraud trial, six years after UAE's largest private hospital group collapsed

The criminal trial of Bavaguthu Raghuram Shetty, founder of NMC Health, is set to open on charges of concealing $5.4 billion in liabilities that collapsed the UAE's largest private hospital group in 2020.

How the collapse unfolded

At its peak, NMC Health operated more than 200 facilities across the UAE, Saudi Arabia, and other Gulf markets, and traded on the London Stock Exchange as a FTSE 100 constituent with a market capitalisation above $8 billion. The collapse began in December 2019, when US short-seller Muddy Waters Research published a report questioning the integrity of NMC's balance sheet. Investigations by PwC, appointed as administrators, uncovered liabilities the company had not disclosed to investors or regulators. Administration followed in April 2020.

Among the creditors left exposed were Abu Dhabi Commercial Bank and Emirates NBD, alongside a syndicate of international lenders. By disclosed liability amount, NMC ranked among the largest accounting scandals in London Stock Exchange history. Six years of administrator proceedings, asset sales, and creditor negotiations have produced partial recoveries, but significant claims remain unresolved.

Regulatory changes that followed

The NMC collapse directly shaped how Abu Dhabi and Dubai now license private healthcare operators. Three changes took effect in the years after 2020:

• The Department of Health Abu Dhabi (DOH) and Dubai Health Authority (DHA) tightened facility licensing reviews to include scrutiny of ownership structures and financial disclosures.
• The Ministry of Health and Prevention (MOHAP) updated accreditation standards to require financial-sustainability assessments as a condition of multi-emirate licensing.
• Both DOH and DHA introduced periodic financial reporting requirements tied to licence renewal.

Boards running private hospital groups in the UAE now face a regulatory environment built partly in response to NMC's governance failures. DOH and DHA have tied licence renewal to governance compliance, and MOHAP's updated accreditation standards apply to any operator seeking a multi-emirate licence.

What operators and investors are watching

Trial proceedings are expected to run for several months. A conviction would test whether UAE courts can deliver accountability at the scale of a $5.4 billion fraud in a licensed healthcare market. An acquittal, or prolonged appeals, would extend legal uncertainty around outstanding creditor claims and delay final asset resolution.

Private equity and institutional investors who re-entered UAE healthcare after NMC's collapse, drawn by the consolidation opportunity it created, are watching the verdict. Mediclinic Middle East and Aster DM Healthcare both acquired former NMC assets at distressed prices. The trial's outcome will not alter those transactions, but a conviction would establish the legal ceiling for corporate misconduct in a sector that has absorbed significant institutional capital since 2020.